BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23832494)

  • 1. Costunolide inhibits osteoclast differentiation by suppressing c-Fos transcriptional activity.
    Cheon YH; Song MJ; Kim JY; Kwak SC; Park JH; Lee CH; Kim JJ; Kim JY; Choi MK; Oh J; Kim YC; Yoon KH; Kwak HB; Lee MS
    Phytother Res; 2014 Apr; 28(4):586-92. PubMed ID: 23832494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esculetin attenuates receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation through c-Fos/nuclear factor of activated T-cells c1 signaling pathway.
    Baek JM; Park SH; Cheon YH; Ahn SJ; Lee MS; Oh J; Kim JY
    Biochem Biophys Res Commun; 2015 May; 461(2):334-41. PubMed ID: 25887803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
    Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
    Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Coumarin Derivative 5'-Hydroxy Auraptene Suppresses Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways.
    Abdallah BM; Ali EM; Elsawy H; Badr GM; Abdel-Moneim AM; Alzahrani AM
    Biomed Res Int; 2019; 2019():9395146. PubMed ID: 31976330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stauntonia hexaphylla (Lardizabalaceae) leaf methanol extract inhibits osteoclastogenesis and bone resorption activity via proteasome-mediated degradation of c-Fos protein and suppression of NFATc1 expression.
    Cheon YH; Baek JM; Park SH; Ahn SJ; Lee MS; Oh J; Kim JY
    BMC Complement Altern Med; 2015 Aug; 15():280. PubMed ID: 26271279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis.
    Kim JY; Cheon YH; Yoon KH; Lee MS; Oh J
    BMB Rep; 2014 Aug; 47(8):451-6. PubMed ID: 24314143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eriodictyol Inhibits RANKL-Induced Osteoclast Formation and Function Via Inhibition of NFATc1 Activity.
    Song F; Zhou L; Zhao J; Liu Q; Yang M; Tan R; Xu J; Zhang G; Quinn JM; Tickner J; Huang Y; Xu J
    J Cell Physiol; 2016 Sep; 231(9):1983-93. PubMed ID: 26754483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocatechuic Acid Attenuates Osteoclastogenesis by Downregulating JNK/c-Fos/NFATc1 Signaling and Prevents Inflammatory Bone Loss in Mice.
    Park SH; Kim JY; Cheon YH; Baek JM; Ahn SJ; Yoon KH; Lee MS; Oh J
    Phytother Res; 2016 Apr; 30(4):604-12. PubMed ID: 26792397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression.
    Kwak HB; Kim HS; Lee MS; Kim KJ; Choi EY; Choi MK; Kim JJ; Cho HJ; Kim JW; Bae JM; Kim YK; Park BH; Ha H; Chun CH; Oh J
    Biol Pharm Bull; 2009 Jan; 32(1):45-50. PubMed ID: 19122279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos.
    Ha J; Choi HS; Lee Y; Lee ZH; Kim HH
    Int Immunopharmacol; 2009 Jun; 9(6):774-80. PubMed ID: 19285574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
    Kim JY; Oh HM; Kwak SC; Cheon YH; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2015; 38(1):66-74. PubMed ID: 25744460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
    Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
    Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects of Aronia melanocarpa 'Viking' Extracts in Attenuating RANKL-Induced Osteoclastic Differentiation by Inhibiting ROS Generation and c-FOS/NFATc1 Signaling.
    Ghosh M; Kim IS; Lee YM; Hong SM; Lee TH; Lim JH; Debnath T; Lim BO
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29518052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
    Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.